observational
    2021

    Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study

    Keizman D, Frenkel M, Peer A

    Published in Nutrients

    Key Findings

    After 18 months, 46 of 59 patients had a favourable PSA response with the galectin-3 antagonist modified citrus pectin, with no severe toxicity.

    Conclusions

    Consistent uncontrolled signal warranting randomised testing.

    Limitations

    Single arm, industry supplied product.

    Supplements Studied

    Forty-six of fifty-nine patients had a favourable PSA response after 18 months of modified citrus pectin.

    Outcomes Measured

    Prostate Health

    Most patients with biochemically relapsed prostate cancer had a favourable PSA response on modified citrus pectin.

    Related Health Concerns

    Cancer
    Prostate Cancer

    Study Details

    Year:2021
    Sample Size:59
    Duration:78 weeks
    Quality Score:5/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.